AU2021221106A1 - Omecamtiv mecarbil tablet - Google Patents
Omecamtiv mecarbil tablet Download PDFInfo
- Publication number
- AU2021221106A1 AU2021221106A1 AU2021221106A AU2021221106A AU2021221106A1 AU 2021221106 A1 AU2021221106 A1 AU 2021221106A1 AU 2021221106 A AU2021221106 A AU 2021221106A AU 2021221106 A AU2021221106 A AU 2021221106A AU 2021221106 A1 AU2021221106 A1 AU 2021221106A1
- Authority
- AU
- Australia
- Prior art keywords
- tablet formulation
- omecamtiv mecarbil
- film coating
- core
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062972506P | 2020-02-10 | 2020-02-10 | |
| US62/972,506 | 2020-02-10 | ||
| PCT/US2021/017429 WO2021163172A1 (en) | 2020-02-10 | 2021-02-10 | Omecamtiv mecarbil tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2021221106A1 true AU2021221106A1 (en) | 2022-09-22 |
Family
ID=74858801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021221106A Pending AU2021221106A1 (en) | 2020-02-10 | 2021-02-10 | Omecamtiv mecarbil tablet |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230090391A1 (https=) |
| EP (1) | EP4103159A1 (https=) |
| JP (1) | JP7696353B2 (https=) |
| CN (1) | CN115279349A (https=) |
| AU (1) | AU2021221106A1 (https=) |
| BR (1) | BR112022015457A2 (https=) |
| CA (1) | CA3168513A1 (https=) |
| IL (1) | IL295490A (https=) |
| WO (1) | WO2021163172A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2522579T3 (es) | 2004-06-17 | 2014-11-17 | Cytokinetics, Inc. | Compuestos, composiciones y métodos |
| SG11201507258PA (en) | 2013-03-14 | 2015-10-29 | Amgen Inc | Heterocyclic compounds and their uses |
| DK3645002T3 (da) | 2017-06-30 | 2024-12-16 | Amgen Inc | Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer |
| AU2018294254C1 (en) | 2017-06-30 | 2022-10-13 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| PT3594199T (pt) | 2018-07-09 | 2020-09-04 | Amgen Inc | 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação |
| MA53226A (fr) | 2018-08-17 | 2021-11-24 | Amgen Inc | Sel et formes cristallines d'omecamtiv mecarbil |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| DK4243825T3 (da) | 2020-11-12 | 2025-12-01 | Amgen Inc | Omecamtiv mecarbil til behandling af hjerteinsattsvigt hos udvalgte patientgrupper |
| IL305751A (en) | 2021-03-10 | 2023-11-01 | Amgen Inc | SYNTHESIS OF OMECAMTIV MECARBIL |
| US20250161298A1 (en) * | 2022-02-22 | 2025-05-22 | Yale University | Methods of treating, ameliorating, or preventing heart failure, and methods of promoting heart muscle growth |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2419007T3 (es) * | 2005-12-15 | 2013-08-19 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y procedimientos |
| SG11201507258PA (en) * | 2013-03-14 | 2015-10-29 | Amgen Inc | Heterocyclic compounds and their uses |
| US9895308B2 (en) * | 2013-03-14 | 2018-02-20 | Amgen Inc. | Heterocyclic compounds and their uses |
| DK3645002T3 (da) * | 2017-06-30 | 2024-12-16 | Amgen Inc | Fremgangsmåder til behandling af hjertesvigt med hjerte-sarkomer-aktivatorer |
-
2021
- 2021-02-10 US US17/798,531 patent/US20230090391A1/en active Pending
- 2021-02-10 WO PCT/US2021/017429 patent/WO2021163172A1/en not_active Ceased
- 2021-02-10 CN CN202180013878.7A patent/CN115279349A/zh active Pending
- 2021-02-10 EP EP21710140.1A patent/EP4103159A1/en active Pending
- 2021-02-10 IL IL295490A patent/IL295490A/en unknown
- 2021-02-10 JP JP2022548433A patent/JP7696353B2/ja active Active
- 2021-02-10 BR BR112022015457A patent/BR112022015457A2/pt unknown
- 2021-02-10 AU AU2021221106A patent/AU2021221106A1/en active Pending
- 2021-02-10 CA CA3168513A patent/CA3168513A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4103159A1 (en) | 2022-12-21 |
| US20230090391A1 (en) | 2023-03-23 |
| JP2023513249A (ja) | 2023-03-30 |
| IL295490A (en) | 2022-10-01 |
| CN115279349A (zh) | 2022-11-01 |
| BR112022015457A2 (pt) | 2022-10-04 |
| JP7696353B2 (ja) | 2025-06-20 |
| WO2021163172A1 (en) | 2021-08-19 |
| CA3168513A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230090391A1 (en) | Omecamtiv mecarbil tablet | |
| JP4463875B2 (ja) | 医薬組成物 | |
| RU2456989C2 (ru) | Твердые лекарственные формы, содержащие тадалафил | |
| TWI590835B (zh) | 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物 | |
| KR101774676B1 (ko) | 히드로모르폰 및 날록손을 포함하는 제약 조성물 | |
| CA2845228C (en) | Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds | |
| US20160287541A1 (en) | Modified Release Tranexamic Acid Formulation | |
| US20200101053A1 (en) | Method of treating heart failure with preserved ejection fraction by administering milrinone | |
| TW202038917A (zh) | 包含托法替尼或其藥學上可接受的鹽類的延長釋放配方及其製備方法 | |
| JP2021518423A (ja) | レナリドミドの経口用コーティング錠剤組成物 | |
| EP3437645B1 (en) | Film-coated tablet having high chemical stability of active ingredient | |
| CN104997748B (zh) | 一种治疗高血压急症的硝苯地平缓释片剂及其制备工艺 | |
| WO2004078111A2 (en) | Extended release minocycline compositions and processes for their preparation | |
| TW200808358A (en) | Galenical formulations of organic compounds | |
| WO2009027786A2 (en) | Matrix dosage forms of varenicline | |
| EP3796908B1 (en) | Controlled release propiverine formulations | |
| JP2022544167A (ja) | ニトロキソリンを含む医薬組成物、ニトロキソリン経口固形錠剤、その調製方法、及びその使用 | |
| WO2023279381A1 (zh) | 普瑞巴林的药物组合物及其制备方法和用途 | |
| US20080182908A1 (en) | Pharmaceutical compositions comprising memantine | |
| RU2742745C1 (ru) | Лекарственная форма в виде капсулы, содержащая таблетки с диметилфурмаратом | |
| WO2021116244A1 (en) | Modulation of drug release and bioavailability of compositions containing dolutegravir sodium and other anti hiv drugs | |
| KR101798184B1 (ko) | 약물 방출제어용 조성물 | |
| WO2023044024A1 (en) | Novel ph dependent coating drug delivery system | |
| WO2025190465A1 (en) | Stable pharmaceutical composition containing selexipag and process for the preparation thereof | |
| HK1239565A (en) | Extended release tablet of cyclobenzaprine |